Nucleai, maker of an AI-powered pathology platform that aims to predict a patient’s response to treatment, raised $33 million in Series B funding, per Mobi Helath News.
The round was led by Section 32 and Sanofi Ventures, with participation from existing investors including Debiopharm, Fosun RZ Capital, Vertex Ventures and Grove Ventures. The startup said the latest round brings its total raise to nearly $50 million.
